Grunenthal snags a PhIII-ready orphan drug in Thar Pharma buyout
Thar Pharmaceuticals won’t be pushing ahead with its IPO after all. The Pittsburgh-based biotech is getting bought out by Germany’s Grunenthal, which was attracted to the deal by Thar’s leading program, the Phase III-ready rare disease drug T121.
Thar outlined its case to investors in its S-1, spotlighting a move to take an IV-formulated drug and make it into a pill for a rare condition called complex regional pain syndrome, or CRPS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.